Abstract: AIM: To investigate the clinical effects of hemopoietic stem cell mobilized by Hyper-CVAD/MA (methopterin+cytarabine)+granulocyte colony-stimulating factor (G-CSF) regimen on lymphoma patients.METHODS: 25 patients with aggressive non-Hodgkin lymphoma (NHL) were randomly divided into two groups, which were separately applied with cyclophosphamide+G-CSF regimen (Control group) and Hyper-CVAD/MA+G-CSF regimen (Study group) to mobilize hemopoietic stem cells. And then mobilization and safety were detected.RESULTS: The data in the study group was successfully collected on the first try, the times of collection in the study group was significant reduced compared to that of the control group (P<0.01); The total number of CD₃₄⁺ cells in the study group and control group were separately (5.45±4.63)×10⁶/kg and (3.04±0.74)×10⁶/kg, which had no significant difference(P>0.05); There was a similar incidence rate of infection between the two groups (P>0.05); In addition, there was no significant difference in the incidence rate of thrombocytopenia between the two groups(P>0.05).CONCLUSION: Hemopoietic stem cells mobilized by Hyper-CVAD/MA+G-CSF on lymphoma patients was not only safe and effective but also easy to operate. Addionally, it played the role of in vivo purging prior to transplantation. Therefore, it gained two advantages by this regimen.

Key words: Lymphoma, Hyper-CVAD/MA regimen, Hemopoietic stem cells